Dr Reddy S Lab Shares
- All
- News
- Videos
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Labs Sheds 11% After Profit Falls 1.5% To Rs 570 Crore In June Quarter
Dr Reddy's Share Price Today: On Tuesday, Dr Reddy's Labs opened on the BSE at Rs 5,421, inching to an intra day high of Rs 5,445, and an intra day low of Rs 4,786.26, so far
-
Shilpa Medicare Rallies 26% In Two Days On Tie Up To Make Sputnik Vaccine
Shilpa Medicare rallied for second straight session on Tuesday after it tied up with Dr Reddy's Labs to make Sputnik V Vaccine.
-
Dr Reddy's Labs Slides Despite Government Go-Ahead For Sputnik Vaccine
The company's shares had opened at a high of Rs 5,200 per share. They had closed at Rs 4,989 on Monday.
-
Stocks To Watch: Coal India, Dr Reddy's Labs, Auto Shares In Focus Today
List of Stocks in Focus Today: Auto companies, including Tata Motors, Hero MotoCorp and Eicher Motors, are set to hog the limelight on the bourses after reporting stellar sales performance for the month of November
-
Dr Reddy's Isolates Data Centre Services After Cyberattack, Shares Fall 4%
Cyber-Attack: Dr Reddy's Labs said on Thursday it had isolated all its data center services as a preventive measure following a cyber-attack.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Dr Reddy's Labs Gains On Launching Eye Allergy Drop In US Market
Olopatadine Hydrochloride Ophthalmic Solution USP is equivalent of Novartis's Pataday and is indicated for the temporary relief of itchy eyes .
-
Sensex Falls Over 350 Points; Metal, Banking Shares Worst Hit
Dr Reddy's Labs was top Nifty gainer, the stock rose 3 per cent to Rs 4,763 after it announced launch of eye allergy drop medicine in the US market.
-
Dr Reddy's Labs Reports Profit Of Rs 663 Crore In June Quarter
The company said its research and development (R&D) expenses stood at Rs 361 crore in the quarter ended June 30.
-
Sensex Falls For Third Straight Day On Global Growth Concerns
Seventeen of 19 sector gauges compiled by BSE ended lower led by the S&P BSE Healthcare Index's nearly 2 per cent decline.
-
Dr Reddy's Lab Gets EIR For 2 Facilities, Shares Jump 7%
Dr Reddy's Laboratories said it has received zero observations for its custom pharmaceutical services facility, technology development centre, at Miyapur in Hyderabad after audit of the facility by the USFDA.
-
Sensex Edges Higher; Dr Reddy's Lab Surges Nearly 7%
Dr Reddy's Lab was the top gainer in Nifty, up 6.8 per cent. Shares of the drug maker surged on reports of settlement for a drug.
-
German Regulator Denies GMP Nod To Dr Reddy Labs Unit
Shares of Dr Reddy's Laboratories were down 4.82 per cent from its previous close.
-
Dr.Reddy's First-Quarter Profit Slumps 57%
The company, among India's top 5 drugmakers, reported a net profit after tax and share of profit of associates of Rs 66.6 crore, versus Rs 154 crore a year ago, the company said on Thursday.
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Labs Sheds 11% After Profit Falls 1.5% To Rs 570 Crore In June Quarter
Dr Reddy's Share Price Today: On Tuesday, Dr Reddy's Labs opened on the BSE at Rs 5,421, inching to an intra day high of Rs 5,445, and an intra day low of Rs 4,786.26, so far
-
Shilpa Medicare Rallies 26% In Two Days On Tie Up To Make Sputnik Vaccine
Shilpa Medicare rallied for second straight session on Tuesday after it tied up with Dr Reddy's Labs to make Sputnik V Vaccine.
-
Dr Reddy's Labs Slides Despite Government Go-Ahead For Sputnik Vaccine
The company's shares had opened at a high of Rs 5,200 per share. They had closed at Rs 4,989 on Monday.
-
Stocks To Watch: Coal India, Dr Reddy's Labs, Auto Shares In Focus Today
List of Stocks in Focus Today: Auto companies, including Tata Motors, Hero MotoCorp and Eicher Motors, are set to hog the limelight on the bourses after reporting stellar sales performance for the month of November
-
Dr Reddy's Isolates Data Centre Services After Cyberattack, Shares Fall 4%
Cyber-Attack: Dr Reddy's Labs said on Thursday it had isolated all its data center services as a preventive measure following a cyber-attack.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Dr Reddy's Labs Gains On Launching Eye Allergy Drop In US Market
Olopatadine Hydrochloride Ophthalmic Solution USP is equivalent of Novartis's Pataday and is indicated for the temporary relief of itchy eyes .
-
Sensex Falls Over 350 Points; Metal, Banking Shares Worst Hit
Dr Reddy's Labs was top Nifty gainer, the stock rose 3 per cent to Rs 4,763 after it announced launch of eye allergy drop medicine in the US market.
-
Dr Reddy's Labs Reports Profit Of Rs 663 Crore In June Quarter
The company said its research and development (R&D) expenses stood at Rs 361 crore in the quarter ended June 30.
-
Sensex Falls For Third Straight Day On Global Growth Concerns
Seventeen of 19 sector gauges compiled by BSE ended lower led by the S&P BSE Healthcare Index's nearly 2 per cent decline.
-
Dr Reddy's Lab Gets EIR For 2 Facilities, Shares Jump 7%
Dr Reddy's Laboratories said it has received zero observations for its custom pharmaceutical services facility, technology development centre, at Miyapur in Hyderabad after audit of the facility by the USFDA.
-
Sensex Edges Higher; Dr Reddy's Lab Surges Nearly 7%
Dr Reddy's Lab was the top gainer in Nifty, up 6.8 per cent. Shares of the drug maker surged on reports of settlement for a drug.
-
German Regulator Denies GMP Nod To Dr Reddy Labs Unit
Shares of Dr Reddy's Laboratories were down 4.82 per cent from its previous close.
-
Dr.Reddy's First-Quarter Profit Slumps 57%
The company, among India's top 5 drugmakers, reported a net profit after tax and share of profit of associates of Rs 66.6 crore, versus Rs 154 crore a year ago, the company said on Thursday.
